11. |
Accrued Expenses and Other Long-Term Liabilities |
Other accrued expenses consisted of the
following as of December 31, 2020 and 2019:
|
|
December 31, 2020 |
|
|
December 31, 2019 |
|
Accrued royalties |
|
$ |
2,710 |
|
|
$ |
1,934 |
|
Contingent consideration |
|
|
398 |
|
|
|
502 |
|
Upfront Medicare payment |
|
|
2,066 |
|
|
|
- |
|
Operating lease liability |
|
|
1,027 |
|
|
|
1,321 |
|
Financing lease liability |
|
|
177 |
|
|
|
184 |
|
Deferred revenue |
|
|
54 |
|
|
|
457 |
|
Payable to CGI |
|
|
- |
|
|
|
888 |
|
Accrued sales and marketing - diagnostics |
|
|
51 |
|
|
|
197 |
|
Accrued lab costs - diagnostics |
|
|
161 |
|
|
|
163 |
|
Accrued professional fees |
|
|
854 |
|
|
|
1,399 |
|
Taxes payable |
|
|
334 |
|
|
|
403 |
|
Unclaimed property |
|
|
565 |
|
|
|
565 |
|
All others |
|
|
1,398 |
|
|
|
1,463 |
|
Total other accrued expenses |
|
$ |
9,795 |
|
|
$ |
9,476 |
|
Other long-term liabilities consisted of
the following as of December 31, 2020 and 2019:
|
|
December 31, 2020 |
|
|
December 31, 2019 |
|
Warrant liability |
|
$ |
21 |
|
|
$ |
82 |
|
Uncertain tax positions |
|
|
4,342 |
|
|
|
4,081 |
|
Deferred revenue |
|
|
136 |
|
|
|
269 |
|
Other |
|
|
138 |
|
|
|
141 |
|
Total other long-term liabilities |
|
$ |
4,637 |
|
|
$ |
4,573 |
|
In the third quarter of 2020,
the Company reversed approximately $1.2 million of bonus accrual that was accrued in 2019 after it was determined it would not be paid
out.
|